Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3459-3468

  Britten, C D ^a   Baker, S D ^a   Denis, L J ^a   Johnson, T ^a   Drengler, R ^a   Siu, L L ^a   Duchin, K ^a   Kuhn, J ^a   Rowinsky, E K ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450; DRUG METABOLITE; GLYCOPROTEIN P; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER SIMULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 0033822666     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Promotion of microtubule assembly in vitro by Taxol
2. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations
3. Paclitaxel (Taxol)
4. Taxanes in the treatment of breast cancer: A prodigy comes of age
5. Role of taxanes in lung cancer chemotherapy
6. 1 mice
7. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel
8. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low dose and long versus short infusion
9. Cremophor. Pharmacological activity of an 'inert' solubiliser
10. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
11. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
12. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
13. Multidrug resistance
14. Biochemistry of multidrug resistance mediated by the multidrug transporter
15. Multidrug resistance in the laboratory and clinic
16. P-glycoprotein: A mediator of multidrug resistance in tumor cells
17. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
18. Expression of a multi-drug resistance gene in human cancers
19. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues
20. Genetic dissection of the function of mammalian P-glycoproteins
21. Limited oral bioavailability and active epithelia/excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
22. 6α-Hydroxytaxol: Isolation and identification of the major metabolite of Taxol in human liver microsomes
23. Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8
24. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation
25. Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
26. Taxol metabolism and disposition in cancer patients
27. Variability in human cytochrome P450 metabolism
28. Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium Report
29. Human cytochrome 450 enzymes
30. The immunocytochemical localisation and distribution of cytochrome P450 in normal human hepatic and extra-hepatic tissues with a monoclonal antibody to human cytochrome P450
31. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
32. Molecular and physical mechanisms of first-pass extraction
33. P-glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory potencies
34. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
35. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
36. Use of cyclosporin to improve oral bioavailability of paclitaxel
37. Guidelines for Reporting of Adverse Drug Reactions
38. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
39. A high performance liquid chromatographic procedure for the quantitative determination of paclitaxel in human plasma
40. Quantification of paclitaxel metabolites in human plasma
41. The effects of cyclosporine and cyclosporine metabolites in experimental small intestinal transplantation
42. A program package for simulation and parameter estimation in pharmacokinetic systems
43. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
44. Paclitaxel and docetaxel
45. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
46. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion
47. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A Phase I/II trial of 96-hour infusion
48. Clinical pharmacology of oral paclitaxel in a dose escalating study
49. Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment
50. Role of intestinal P-glycoprotein in interpatient variation in the oral bioavailability of cyclosporine
51. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation
52. Clinical studies with modulators of multidrug resistance